Stockscreener 앱 받기
7.66
2.54%
-0.20
시간 외 거래:
7.64
-0.02
-0.26%
Blackrock Innovation And Growth Term Trust 주식(BTX)의 최신 뉴스
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eterna Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Eterna Therapeutics faces Nasdaq delisting over share price - Investing.com India
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - Defense World
BNY Mellon Ultra Short Income ETF (NYSEARCA:BKUI) Stock Price Up 0% – Should You Buy? - Defense World
Athersys (NASDAQ:ATHX) Research Coverage Started at StockNews.com - Defense World
StockNews.com Begins Coverage on Avangrid (NYSE:AGR) - Defense World
General Electric (NYSE:GE) Shares Bought by Creative Planning - Defense World
Week Ahead (Apr.12- Apr.16): PDUFA Dates, Data Readouts (RCUS, ATXI, MRTX, KDNY…) - RTTNews
‘Today you’re going to die’. Man ‘disrespected’ at family event kills cousin, MN cops say - Kansas City Star
15-Year-Old Shot Outside Brooklyn High School: Police - Patch
Teen Shot Outside Brooklyn High School - BK Reader
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $87.23 Million Holdings in Intuit Inc. (NASDAQ:INTU) - MarketBeat
Eterna Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Eterna Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Itau Unibanco Holding S.A. Takes Position in Bristol-Myers Squibb (NYSE:BMY) - Defense World
Video NYPD releases body camera video of police shooting at Brooklyn Subway station - ABC News
Brooklyn Farebeater Who Cops Shot Pleads Not Guilty From Hospital Bed - Brooklyn, NY Patch
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com - MarketBeat
Eterna Therapeutics sets September 27 for annual meeting - Investing.com
Exclusive: RNA firm Eterna Therapeutics buys neighboring startup for $50M - The Business Journals
Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights - GlobeNewswire
Kevin D’Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer - Business Wire
ERNA Stock Price and Chart — NASDAQ:ERNA - TradingView
Eterna Therapeutics Completes Name Change, Acquires Option - GlobeNewswire
Brooklyn hails immunotherapy for achieving 'primary objective'—but fails the primary endpoint - Fierce Biotech
“Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy” published in Chemical Reviews, selected as VINSE Spotlight Publication - Vanderbilt University
SpyBiotech Appoints Mark Leuchtenberger as Chief Executive Officer - citybiz
iPSC-derived dopamine progenitor cell therapy in Parkinson’s disease - RegMedNet
Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement - StockTitan
Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index - StockTitan
Longeveron: A Meme Stock That Will Oscillate Before Dropping (NASDAQ:LGVN) - Seeking Alpha
New R&D Center Will Focus on Cell-based Therapies - Sickle Cell Disease News
7 Top-Rated Pharmaceutical Companies to Invest In for July - InvestorPlace
Swedish MPA Approves Atossa Therapeutics Inc (NASDAQ: ATOS) To Conduct Phase 2 Clinical Trial Of Oral Endoxifen To Reduce Mammographic Breast Density - BP Journal
10 Top Penny Stocks On Robinhood To Watch Right Now Before July 2021 - Penny Stocks
Brooklyn Immunotherapeutics Inc (NYSEAMERICAN: BTX) Incorporates R&D Center In Cambridge, Massachusetts To Develop mRNA-based Gene Editing/ Cellular Therapies - BP Journal
Brooklyn ImmunoTherapeutics Stock Rises After Novellus Therapeutics Buyout Deal - Benzinga
Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholder Update Call - StockTitan
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing - Business Wire
Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc. - Business Wire
CDE China Grants IND Approval For Vicineum Of Sesen Bio Inc (NASDAQ:SESN) - BP Journal
Christopher Rohde, Ph.D. to Join Scientific Advisory Board of Brooklyn ImmunoTherapeutics - citybiz
Citius Pharmaceuticals Inc (NASDAQ:CTXR) Reports Strong Presence Of Clinical Trial Staff, Investigators, And Referring Physicians In A Webinar On Mino-Lok Phase 3 Clinical Trial - BP Journal
Brooklyn ImmunoTherapeutics: Time To Sell (NYSE:BTX) - Seeking Alpha
1.81%
0.82%
자본화:
|
볼륨(24시간):